Vaxcyte, Inc. (PCVX)

Vaxcyte Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	611.51	397.45	834.66	68.99	386.2	58.98
Short-Term Investments	875.01	682.78	96.72	176.99	0	0
Cash & Cash Equivalents	1,487	1,080	931.38	245.97	386.2	58.98
Cash Growth	80.83%	15.98%	278.65%	-36.31%	554.84%	-10.76%
Other Current Assets	30.55	15.73	11.18	10.38	2.8	2.75
Total Current Assets	1,517	1,096	942.56	256.35	389	61.72
Property, Plant & Equipment	113.74	110.62	31.65	35.91	3.27	3.39
Long-Term Investments	414.35	163.78	27.42	27.99	0	0
Other Long-Term Assets	46.14	37.56	4.56	4.09	0.55	0.58
Total Long-Term Assets	574.23	311.96	63.62	67.99	3.82	3.98
Total Assets	2,091	1,408	1,006	324.34	392.83	65.7
Accounts Payable	21.72	14.59	9.8	6.76	29.79	3.38
Current Debt	7.2	7.11	5.91	5.28	0	0
Other Current Liabilities	58.19	123.64	24.82	16.68	17.08	7.68
Total Current Liabilities	87.1	145.34	40.53	28.72	46.86	11.05
Long-Term Debt	20.22	22.11	12.03	11.51	0	0
Other Long-Term Liabilities	0	0	0.01	0.1	0.12	0.71
Total Long-Term Liabilities	20.22	22.11	12.04	11.6	0.12	0.71
Total Liabilities	107.32	167.45	52.57	40.32	46.98	11.76
Total Debt	27.42	29.22	17.94	16.78	0	0
Debt Growth	65.33%	62.89%	6.90%	-	-	-
Retained Earnings	-1,019.41	-924.39	-522.13	-298.64	-198.56	-109.35
Comprehensive Income	2.89	0.18	-0.36	-0.24	0	0
Shareholders' Equity	1,984	1,240	953.61	284.02	345.84	-106.37
Net Cash / Debt	1,459	1,051	913.44	229.19	386.2	58.98
Net Cash / Debt Growth	81.15%	15.06%	298.55%	-40.66%	554.84%	-10.55%
Net Cash Per Share	13.06	10.82	14.08	4.41	13.07	15.54
Working Capital	1,430	950.62	902.03	227.63	342.14	50.67
Book Value Per Share	17.76	12.77	14.70	5.47	11.71	-28.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).